Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Clinicians now have a second option in treating trichomoniasis, which accounts for nearly one-third of the 15.4 million cases of sexually transmitted diseases (STDs) in the United States. The Food and Drug Administration (FDA) has approved Tindamax (tinidazole) for the treatment of trichomoniasis, giardiasis, intestinal amebiasis, and amebic liver abscess.

STD Quarterly: Trichomoniasis drug given FDA approval